About
Fusion Pharma develops targeted alpha therapeutics by linking alpha-emitting isotopes to molecules that selectively target cancer cell biomarkers, using proprietary Fast-Clear™ technology to improve drug safety and enable scalable manufacturing.
Explore Fusion Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.